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Brain HealtH
A new dawn of preventing dementia by preventing 
cerebrovascular diseases
Yuesong Pan and colleagues discuss the relation between cerebrovascular diseases and 
impairment of cognition, with an emphasis on a chance to prevent dementia by preventing 
cerebrovascular diseases
Cerebrovascular diseases and dementia are two leading con-tributors to impairment of brain health and neurological disability in older people.1 The 
prevalence of these two neurological dis-
orders has increased in recent years as the 
population has aged and grown. Globally, 
an estimated 42.4 million cases of stroke 
occurred in 2015,2 and approximately 50 
million cases of dementia (including Alz-
heimer’s disease, vascular dementia, and 
other dementias) occurred in 2018.3 Strat-
egies for preventing and treating stroke 
have progressed substantially in recent 
years, but no effective treatment yet exists 
for Alzheimer’s disease. Recent studies 
have shown that many vascular risk fac-
tors and unfavourable lifestyle factors are 
shared predictors of stroke and dementia,4 
and incident cerebrovascular diseases may 
precipitate a decline in cognitive function 
or dementia.5 6 This suggests that some cog-
nitive impairment and dementia might be 
prevented by preventing cerebrovascular 
diseases.7
Cognitive impairment in cerebrovascular 
diseases
Cerebrovascular diseases include a variety 
of medical conditions that affect the blood 
vessels of the brain and the cerebral circu-
lation. These include conditions that may 
cause acute interruption of cerebral cir-
culation and subsequent acute neuronal 
damage, such as ischaemic or haemor-
rhagic stroke, and disorders that may cause 
chronic pathological changes in small ves-
sels and neurological dysfunction, such 
as cerebral small vessel diseases. Patients 
with cerebrovascular diseases, both acute 
and chronic, usually have multidimen-
sional functional impairments to the brain 
and an increased risk of cognitive impair-
ment and dementia.
Globally, approximately one in four 
adults will develop stroke in their lifetime 
from the age of 25 years onwards.8 
Functional impairments to the brain due to 
stroke vary, but physical disability, aphasia, 
and dysphagia are common and have 
received the most attention from stroke 
specialists to date. However, many patients 
who survive stroke go on to experience 
cognitive decline, including vascular 
cognitive impairment and other dementias, 
and these aspects have received less 
attention from either stroke specialists or 
dementia specialists. This is unfortunate, as 
incident stroke is associated with an acute 
decline in cognitive function, especially in 
global cognition and executive function.5 
The incidence of post-event dementia at 
one year in patients with the mildest stroke 
symptoms (that is, transient ischaemic 
attack and minor stroke) ranges from 5-8% 
to 19% but may reach more than 34% in 
those with severe stroke, nearly 50 times 
higher than in the general population.6 
9 Cognitive decline also accelerates and 
persists over many years,5 and it could be 
as high as 44% at three years after a minor 
stroke and be the main factor preventing 
independence or return to work.9
Another form of cerebrovascular disease 
that has received less attention from 
neurological specialists is chronic damage 
to the small vessels in the brain. The 
features of cerebral small vessel diseases 
seen on brain imaging include lacunas, 
white matter hyperintensity, and cerebral 
microbleeds, as well as various other 
features. A population based study showed 
that more than 70% of people aged 50 years 
or older presented with at least one kind of 
cerebral small vessel disease.10 Cerebral 
small vessel disease is not fully understood, 
but it is associated with chronic damage to 
small vessels that may lead to blockage or 
leakage of small vessels in the brain.11 As 
the chronic damage accumulates, patients 
with cerebral small vessel disease can 
present with acute stroke syndromes, mild 
cognitive impairment or dementia, gait 
and balance problems, mood disorders, 
and urinary incontinence, depending on 
the location of the lesions.11 Cerebral small 
vessel disease is one of the most common 
causes of vascular dementia and is also 
frequently found alongside Alzheimer’s 
disease pathology.7 11 Cerebral small vessel 
disease is estimated to contribute 45-50% 
of all cases of dementia.11
The cognit ive  consequences  of 
cerebrovascular disease may substantially 
affect patients’ quality of life and cause a 
considerable disease burden for patients 
and their families.9 Compared with other 
brain dysfunctions such as movement 
disorders, cognitive impairment and 
dementia due to cerebrovascular diseases 
are neglected by both patients and 
physicians in all countries, but especially 
in low income and developing countries 
such as China.
Mechanisms of cognitive impairment in 
cerebrovascular diseases
Given the high prevalence of cognitive 
impairment, understanding the mecha-
nisms of cognitive impairment in cerebro-
vascular diseases is pivotal. Understanding 
impairment of brain function due to neu-
ronal damage after stroke is not difficult. 
A recent study suggested that multiple 
infarcts in one hemisphere; involvement 
of strategic regions such as the middle 
and inferior frontal gyri, parietal region, 
and middle temporal gyrus; larger stroke 
lesion volume; and lesions on the left hemi-
sphere were associated with a higher risk 
Key Messages
•   Patients with cerebrovascular dis-
eases, including both stroke and small 
vessel disease, have an increased risk 
of cognitive impairment and dementia
•   Vascular factors contribute to the 
pathophysiological progress of cogni-
tive impairment and dementia, which 
offers a new dawn of preventing 
dementia by preventing cerebrovas-
cular diseases
•   Further studies are needed to under-
stand the mechanisms of cognitive 
impairment and explore effective 
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of dementia after stroke.12 Further studies 
are needed in large populations to confirm 
these findings and enable application of a 
personalised approach in the clinic.
Despite cognitive impairment after 
cerebral small vessel disease being a 
common cause of impairment of brain 
function, its underlying pathogenesis and 
mechanism are poorly understood. Recent 
studies showed that early impairment of 
cognition may be induced by disruption 
of the glio-neuro-vascular unit.7 13 Small 
vessel pathologies due to vascular risk 
factors may induce breakdown in the 
integrity of the blood-brain barrier and 
cerebral blood flow deficits.7 13 Although 
not yet tested in prospective longitudinal 
studies, structural and functional 
alterations of cerebral small vessels 
may trigger the cascade of molecular 
signals (for example, activation of innate 
immunity, vascular oxidative stress, and 
inflammation), leading to disruption of the 
glio-neuro-vascular unit.7 Neurovascular 
dysfunction alters the homeostasis of the 
brain microenvironment and promotes 
accumulation of amyloid and tau protein 
in regions involved in cognition, leading 
to early vascular and neurodegenerative 
cognitive impairment.7 Accumulation of 
amyloid and tau protein in cerebrospinal 
fluid and changes in their concentrations 
in the brain may contribute to patho-
physiological progression from no cognitive 
impairment to mild cognitive impairment to 
Alzheimer’s disease.
Recent progress in imaging techniques 
has provided potential breakthroughs in 
our understanding of the mechanism of 
cognitive impairment. Clinical studies 
have shown endothelial dysfunction in 
cerebral microvessels in cerebral small 
vessel disease, including blood-brain 
barrier dysfunction, dysfunctional blood 
flow, impaired interstitial fluid drainage, 
and white matter rarefaction.11 However, 
challenges still exist to determine what 
types of vascular dysfunction initiate 
or propagate small vessel disease 
pathogenesis, which abnormalities are 
reversible, and why lesion progression 
and symptomatology are so variable 
(box 1).11 Clarification of these questions 
may facilitate identification of potential 
therapeutic targets to improve brain 
function after cerebrovascular diseases.14
Preventing dementia by preventing 
cerebrovascular diseases
Screening for cognitive impairment using 
scales such as the Montreal Cognitive 
Assessment (MoCA) is easy. However, 
although the US Food and Drug Adminis-
tration recently accepted an application 
for the first biological treatment (aduca-
numab) of Alzheimer’s disease, treatment 
of the disease is still disappointing owing 
to the failure of most recent trials targeting 
clearance of amyloid and selective inhibi-
tion of tau protein aggregation to improve 
cognition in Alzheimer’s disease.15 16 
Increasing evidence points to a failure of 
clearance of amyloid and tau rather than 
overproduction as a main problem in Alz-
heimer’s disease, and this failure is related 
to hypertension and other vascular risk 
factors through functional alteration of 
perivascular space clearance, implicat-
ing new directions to prevent dementia 
by preventing cerebrovascular diseases.17 
This may help to identify new therapeutic 
targets to prevent cognitive impairment, 
including protection of the glio-neuro-vas-
cular unit (box 1).14
Cerebrovascular diseases and dementia 
share some, largely modifiable, risk 
factors and protective factors.4 Growing 
clinical evidence shows that vascular risk 
factors contribute to cognitive impairment. 
General cardiovascular risk was shown to 
be associated with longitudinal cognitive 
decline in clinically normal older adults, 
both alone and synergistically with 
β-amyloid burden.18 Adherence to the Life’s 
Simple 7 advice for ideal cardiovascular 
health (stop smoking, eat better, lose 
weight, control cholesterol, get active, 
reduce blood sugar, and manage blood 
pressure) in midlife was associated with 
a lower risk of dementia later in life in 
the Whitehall II cohort study and was 
recommended by the American Heart 
Association/American Stroke Association 
Presidential Advisory to maintain optimal 
brain health.19 20 The Lancet Commission 
on Dementia Prevention, Intervention, 
and Care proposed a life course model of 
dementia risk that reflects how lifestyle 
factors across the lifespan contribute to 
risk of dementia. They estimated that 
12 modifiable lifestyle factors across the 
lifespan accounted for approximately 40% 
of worldwide dementias, among which 
vascular risk factors (midlife hypertension, 
alcohol misuse, and obesity; later life 
smoking, physical inactivity, and diabetes) 
accounted for approximately 11%.21 A 
recent study showed that vascular risk 
factors (diabetes, midlife hypertension, 
midlife obesity, physical inactivity, and 
smoking) accounted for approximately 21% 
of Alzheimer’s disease and 17% of vascular 
dementia.22 Assuming a 20% reduction 
in the prevalence of above vascular risk 
factors, depression, and low educational 
level implied a 6.4% and 6.5% reduction 
in the prevalence of Alzheimer’s disease 
and vascular dementia.22 Considering 
that approximately 90% of stroke is 
attributable to modifiable risk factors,23 
preventing dementia by controlling 
vascular risk factors and cerebrovascular 
diseases may be promising. Nevertheless, 
a systematic review conducted by the 
Agency for Healthcare Research and 
Quality concluded that insufficient high 
strength evidence existed to justify a 
public health campaign to encourage 
people to adopt lifestyle interventions 
to prevent or slow cognitive decline and 
dementia.24
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As cerebrovascular diseases and demen-
tia are so closely interlinked, amelioration 
of vascular risk and vascular damage 
offers a new dawn for preventing not only 
vascular dementia but also mixed and even 
Alzheimer’s dementias, and it may even 
offer alternative routes to clear amyloid 
and tau protein aggregation. Neurons are 
not renewable, and impairment of brain 
function is often irreversible. Therefore, 
very few effective approaches are available 
for patients with cerebrovascular diseases 
and cognitive impairment, although scope 
for repurposing exists. For example, one 
study suggested that nimodipine might 
reduce memory impairment after acute 
ischaemic stroke.25 Similarly, drugs with 
endothelial and glial protection and 
anti-inflammatory properties, such as 
cilostazol, are being trialled to prevent 
and treat cerebral small vessel diseases 
and reduce cognitive impairment (for 
example,  http://www.isrctn.com/
ISRCTN14911850). As cerebral small 
vessel disease is associated with vascular 
risk factors, particularly hypertension, 
intensive control of vascular risk factors 
such as hypertension has been evaluated, 
although with mixed results.14 For example, 
a substudy of the SPRINT MIND (Systolic 
Blood Pressure Intervention Trial Memory 
and Cognition in Decreased Hypertension) 
trial showed that intensive blood pressure 
reduction decreased progression of white 
matter hyperintensities, mild cognitive 
impairment, and probable dementia.26 
The results of these trials indicated that 
patients with cerebrovascular disease or 
vascular risk factors might be a potential 
target population to prevent dementia. As 
cerebrovascular disease and vascular risk 
factors are so common, these converging 
epidemiological and clinical trial results 
justify further efforts to find ways to prevent 
dementia by improving management of 
vascular risk factors and testing drugs 
that may improve the function of the 
endothelium and other parts of the glio-
neuro-vascular unit.
In summary, patients with cerebro-
vascular diseases have a substantial risk 
of cognitive impairment. Vascular factors 
contribute to the pathophysiological 
progress of cognitive impairment, 
providing new opportunities for preventing 
not only vascular dementia but also 
mixed and potentially even Alzheimer’s 
dementias by testing prevention strategies 
that work for cerebrovascular diseases. 
Further studies are needed to understand 
the mechanism by which cerebrovascular 
disease accelerates Alzheimer’s, mixed, 
and vascular dementias and to test 
interventions targeting vascular risk factors 
and people with cerebrovascular diseases 
to prevent dementia.
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